MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: Drug sensitivity profiling also highlighted IAP-, PAK- and MDM2-inhibitors as potentially effective therapeutic options that can be combined with TKIs warranting their testing in personalized treatment strategies of p190-CML.